Novavax Global Commercial Operations and COVID-19 Vaccine Update
Vaccine pipeline
Significant opportunities for future development
Disease
Novavax Clinical-Stage
Product
NVX-CoV23731
Matrix-M
Coronavirus
Variant Strain-Containing
Monovalent or Bivalent²
Matrix-M
Seasonal Influenza
Influenza
(Older Adults)
Matrix-M
Combination Vaccines
COVID/Influenza
Matrix-M
Partnered Clinical-Stage
Malaria
R213
Matrix-M
Novavax Preclinical-Stage
RSV Vaccine4
RSV
Matrix-M
(Older Adults)
Influenza / RSV
Matrix-M
Combination Vaccines
Influenza/COVID / RSV
Matrix-M
Preclinical
Phase 1
Phase 2
Phase 3
Authorized
1. Authorized in select geographies under trade names Novavax COVID-19 Vaccine, Adjuvanted; Covovax TM; and Nuvaxovid. The trade name Nuvaxovid has not yet been approved by the FDA.
2. Ongoing Phase 3 strain change trial.
novavax:
3. Ongoing Phase 3 trial for R21, a malaria candidate developed by the Jenner Institute, University of Oxford and formulated with Matrix-M adjuvant.
4. Clinical development conducted in older adults with previous construct through Phase 3 trial.
© 2023 NOVAVAX. All rights reserved.
26View entire presentation